Serum Vascular Endothelial Growth Factor Concentrations in Hepatocellular Cancer Patients Undergoing Percutaneously Radiofrequency Thermal Ablation
- 1 November 2004
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 16 (sup5) , 7-10
Abstract
Vascular endothelial growth factor (VEGF) is known to play a central role in tumour angiogenesis. However, no data have been published with regard to the clinical-biological significance of serum (S)-VEGF in hepatocellular cancer (HCC) patients undergoing to percutaneously radiofrequency thermal ablation (PRFA). The aim of this study was to assess the modifications of S-VEGF levels in a series of 28 HCC patients in hepatitis C virus-positive cirrhosis before and after PRFA, respectively. Samples of S were taken before, 2 and 5 days after PRFA respectively and VEGF levels were assessed by ELISA. No significant difference was found between pre- and post-VEGF levels (p= n.s.; by Wilcoxon test). We suggest that S-VEGF level is not useful as early predictive marker of response to PRFA.Keywords
This publication has 6 references indexed in Scilit:
- Radiofrequency Ablation of 40 Lung Neoplasms: Preliminary ResultsAmerican Journal of Roentgenology, 2004
- Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls.Oncology Reports, 2004
- Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After SurgeryAnnals of Surgical Oncology, 2003
- Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumoursEuropean Journal of Cancer, 2002
- Percutaneous tumor ablation with radiofrequencyCancer, 2002
- What Is the Role of Vascular Endothelial Growth Factor-Related Molecules in Tumor Angiogenesis?The American Journal of Pathology, 1998